Ademi LLP Scrutinizes Fulcrum Therapeutics Merger Terms

Under the proposed agreement, pre-merger Fulcrum stockholders are slated to retain only 5.0% of the combined entity, while Slate Medicines investors will control 95.0%. This ownership split remains subject to adjustment based on Fulcrum’s net cash position at the closing date. The company intends to contribute approximately $20.3 million in net cash to the new firm while distributing an estimated $270.0 million cash dividend to existing shareholders immediately before the merger concludes.

Ademi LLP is reviewing allegations that the board failed to secure a fair price for stakeholders. The investigation also addresses concerns that the agreement imposes restrictive penalties on potential competing bids, effectively limiting alternative offers. The firm is further examining whether Fulcrum insiders are receiving disproportionate benefits through change-of-control arrangements. Shareholders seeking to participate in the inquiry or review the specific terms of the transaction can contact Guri Ademi at 866-264-3995.